



# HOKKAIDO UNIVERSITY

|                  |                                                                                                                                                                                                             |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title            | Pathological Confirmation of Para-Aortic Lymph Node Status as a Potential Criterion for the Selection of Intrahepatic Cholangiocarcinoma Patients for Radical Resection with Regional Lymph Node Dissection |
| Author(s)        | Nakayama, Tomohide; Tsuchikawa, Takahiro; Shichinohe, Toshiaki et al.                                                                                                                                       |
| Citation         | World Journal of Surgery, 38(7), 1763-1768<br><a href="https://doi.org/10.1007/s00268-013-2433-7">https://doi.org/10.1007/s00268-013-2433-7</a>                                                             |
| Issue Date       | 2014-07                                                                                                                                                                                                     |
| Doc URL          | <a href="https://hdl.handle.net/2115/59525">https://hdl.handle.net/2115/59525</a>                                                                                                                           |
| Rights           | The original publication is available at <a href="http://www.springerlink.com">www.springerlink.com</a>                                                                                                     |
| Type             | journal article                                                                                                                                                                                             |
| File Information | World J Surg_38(7)_1763-1768.pdf                                                                                                                                                                            |



(Full title)

Pathological Confirmation of Para-Aortic Lymph Node Status as a Potential Criterion for the Selection of Intrahepatic Cholangiocarcinoma Patients for Radical Resection with Regional Lymph Node Dissection

(A short title)

The prognosis after curative resection for intrahepatic cholangiocarcinoma without para-aortic lymph node metastasis

(The names of the authors)

Tomohide Nakayama, MD, Takahiro Tsuchikawa, MD, PhD, Toshiaki Shichinohe, MD, PhD, Toru Nakamura MD, PhD, Yuma Ebihara, MD, PhD, Satoshi Hirano, MD, PhD

(The affiliation and address of the authors)

Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine,  
Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan

(Correspondence)

Tomohide Nakayama

Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine,  
Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan

Tel: 81-11-706-7714; Fax: 81-11-706-7158

E-mail address: [hide-nakka@nifty.com](mailto:hide-nakka@nifty.com)

## Abstract

*Background* Para-aortic lymph node (PAN) metastasis has been traditionally defined as distant metastasis. Many studies suggest that lymph node metastasis in intrahepatic cholangiocarcinoma (ICC) is one of the strongest prognostic factors for patient survival; however, the PAN status was not examined separately from regional lymph node metastasis in these reports. Here, we investigated whether regional lymph node metastasis without PAN metastasis in ICC can be classified as resectable disease and whether curative resection can have a prognostic impact.

*Methods* Between 1998 and 2010, 47 ICC patients underwent hepatic resection and systematic lymphadenectomy with curative intent. We routinely performed the dissection of PANs, with frozen-section pathological examinations performed intraoperatively. If PAN metastases were identified, curative resection was abandoned. We retrospectively investigated the prognostic factors for patients survival after curative resection for ICC without PAN metastases, with particular attention on the prognostic impact of lymphadenectomy.

*Results* Univariate analysis identified concomitant portal vein resection, concomitant hepatic artery resection, intraoperative blood loss, intraoperative transfusion, and residual tumor as significant negative prognostic factors. However, lymph node status was not identified as a significant prognostic factor. The 14 patients with node-positive cancer had a survival rate of 20% at 5 years. Based on a multivariate analysis, intraoperative transfusion was an independent prognostic factor associated with a poor prognosis (Risk ratio, 4.161;  $P = 0.0056$ ).

*Conclusions* Regional lymph node metastasis in ICC should be classified as resectable disease, because the survival rate after surgical intervention was acceptable when PAN metastasis was pathologically negative.

## Introduction

Intrahepatic cholangiocarcinoma (ICC) arising from the intrahepatic bile ducts is the second most common hepatic malignancy after hepatocellular carcinoma, accounting for 5–20% of all primary liver cancers [1-4]. The incidence of ICC has increased over recent years, and the prognosis of patients with ICC is generally poor in comparison to that of patients with hepatocellular carcinoma. Currently, surgical resection is the only established therapeutic strategy for ICC; however, the reported 5-year survival rates and the median survival following curative resection ranges only from 8% to 29% and 19 to 31 months, respectively [5-10].

Previous reports have suggested that lymph node metastases have a strong negative impact on postoperative survival in ICC [11-16]; however, para-aortic lymph node (PAN) status has not been examined separately from regional lymph node metastases in these reports. In other cancers, PAN metastases are representative of systemic disease spread and are associated with a minimal benefit from radical surgery [17-19]. Meanwhile, regional lymphadenectomy has been recognized as necessary for biliary tract cancer with nodal disease [20,21]. Hence, an important question is

whether regional lymph node metastases and PAN metastases should be examined separately in terms of survival rate. Here, the study aim was to evaluate whether regional lymph node metastasis in ICC without PAN is a resectable disease.

## Materials and methods

Between September 1998 and August 2010, 77 consecutive patients underwent surgery for ICC at the Division of Surgery, Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine. ICC was defined as adenocarcinoma arising from the second or more peripheral branches of the intrahepatic bile ducts. Patients with combined hepatocellular carcinoma and cholangiocarcinoma were excluded from this study. Of the 77 consecutive patients, 25 were not considered candidates for radical surgery because of PAN metastases diagnosed by intraoperative frozen-section diagnosis ( $n = 12$ ), multiple liver lesions ( $n = 6$ ), peritoneal metastases ( $n=4$ ), and locally advanced tumors ( $n = 3$ ). Postoperatively, PAN status had turned out to be positive by permanent-section examinations in two patients, and three patients received adjuvant chemotherapy during the study period. Therefore, totally 30 patients were excluded from the study. Hence, 47 patients (18 female, 29 male) with a median age of 66 years (range, 40–80 years) who underwent hepatic resection and systematic lymphadenectomy for ICC were included in this study. Complete lymphadenectomy was performed as follows:

Systematic resection of PAN and frozen-section pathological examination were performed during laparotomy prior to curative resection. The para-aortic connective tissue between the levels of the celiac artery and inferior mesenteric artery was resected as PAN (Fig.1). If PAN metastases were identified, curative resection was not performed. If PAN metastases were absent, we performed radical hepatic resection and systematic regional lymphadenectomy. The diagnoses of PAN metastasis were confirmed by permanent section after the surgery. The dissected regional lymph nodes included the lymph node of the hepatoduodenal ligament and those around the common hepatic artery, the portal vein, the common bile duct, and the head of pancreas. We performed lymph node sampling in the right cardiac portion and along the lesser curvature of the stomach only in cases in which the tumor was located within the left hepatic lobe. If sampled nodes were positive, additional lymph node dissection was conducted in the relevant areas.

Preoperatively, all patients underwent three-phase abdominal computed tomography (CT), chest CT, abdominal magnetic resonance imaging (MRI), and liver ultrasonography for preoperative assessment of liver and extrahepatic metastasis. No patients had been administered postoperative adjuvant chemotherapy. None of the patients who underwent curative liver resection were lost to follow-up. At the final assessment (August 2011), 23 patients remained alive, and 24 patients had died. The minimum follow-up period was 12 months or until death, with an overall median follow-up of 54 months (range, 12–155 months).

Tumor stage was defined using the pathological tumor node metastasis (TNM) classification system proposed by the Union International Contra la Cancrum (UICC) 7<sup>th</sup> edition [22]. The

macroscopic tumor gross type was classified into the following categories according to the system proposed by the *Liver Cancer Study Group of Japan*: mass forming type, periductal infiltrating type, intraductal growth type, and other [23]. We analyzed the following clinicopathologic factors likely to influence survival after surgical resection: gender, age, preoperative jaundice, hepatitis virus, preoperative indocyanine green retention rate after 15 minutes, preoperative serum carcinoembryonic antigen level, preoperative serum carbohydrate antigen 19-9 level, concomitant resection of the portal vein, concomitant resection of the hepatic artery, operation time, blood loss, intrahepatic transfusion, macroscopic gross type, tumor number and size, macroscopic gross pattern, lymph node metastases, liver capsular invasion, microscopic vessel (vascular or lymphatic) invasion, perineural invasion, p stage (UICC), and resection margin.

Univariate analysis of overall survival rate was performed using the Kaplan-Meier method and the log-rank test, and multivariate analysis was conducted using a Cox proportional hazard regression model using StatView statistical software (version 5.0; SAS Institute Inc., Cary, NC). Values of  $P < 0.05$  were considered significant.

## Results

### Paraaortic lymphnodes status

A median number of 10.5 PANs were resected per patient. 12 patients were not considered candidates for radical surgery because of PAN metastases by intraoperative frozen-section diagnosis.

In 2 patients, permanent-section examinations revealed positive PAN after surgery, despite negative results from the examination of the intraoperative frozen sections. Therefore, these 2 patients were excluded from this study.

### Surgical Procedures and Complications

The operative data are summarized in Table 1. Hemihepatectomy or trisectionectomy was performed in 43 (92%) of the 47 patients; 28 left hemihepatectomies (segments II–IV  $\pm$  I), 8 right hemihepatectomies (segments V–VIII  $\pm$  I), 5 left trisectionectomies (segments I–V + VIII), and 2 right trisectionectomies (segments I + IV–VIII). We also performed extrahepatic bile duct resection in 37 patients (79%). Concomitant vascular resections were performed in 18 patients, including resection and reconstruction of the hepatic artery ( $n = 5$ ), the portal vein ( $n = 8$ ), and the hepatic vein or inferior vena cava ( $n = 10$ ). Partial resection of the diaphragm was necessary in 3 patients due to direct invasion of the tumor. Two patients died in the hospital because of liver failure, resulting in an in-hospital mortality rate of 4%. One of these patients had undergone right hemihepatectomy with concomitant extrahepatic bile duct resection and septicemia, whereas the other patient had undergone left trisectionectomy with concomitant inferior vena cava resection.

Postoperative complications occurred in 27 (57%) patients. The most common complication was biliary fistula ( $n = 7$ ).

No complication associated with PAN dissection such as postoperative chylous ascites, bleeding, or thrombosis was encountered.

### Clinicopathologic Characteristics

The tumor diameter ranged from 1.0 to 11.0 cm (median, 4.5 cm). Eight patients had multiple tumors. Overall, 43 (86%) R0 resections and 6 R1 resections (1 case demonstrated microscopic involvement of the bile duct stump, while 5 cases had exfoliated stumps) were performed.

### Survival after Surgery and Univariate/Multivariate Analysis for Prognostic Factors

The overall survival rate for all 47 patients who underwent hepatic resection was 51% at 3 years and 28% at 5 years; the median duration of survival was 38 months. Univariate analysis identified 5 significant prognostic factors for survival after surgery; concomitant portal vein resection ( $P = 0.0139$ ), concomitant hepatic artery resection ( $P = 0.0011$ ), blood loss ( $P = 0.0181$ ), intraoperative transfusion ( $P = 0.0006$ ), and residual tumor ( $P = 0.0062$ ) (Table 2). Lymph node status was not a significant prognostic factor ( $P = 0.0886$ ) in univariate analysis. The 14 patients with lymph node metastases had a survival rate of 20% at 5 years, while the survival rate in the absence of lymph

node metastasis was 31% at 5 years (Fig. 2). In multivariate analysis, intraoperative transfusion was an independent prognostic factor associated with poor prognosis (risk ratio, 4.161;  $P = 0.0056$ ) (Table 3).

## Discussion

In our series of 47 patients without PAN metastases, intraoperative transfusion was identified as an independent prognostic factor. The 3- and 5-year overall survival for the 14 patients with positive lymph node metastases was 40% and 20%, respectively. By contrast, the absence or presence of lymph node metastases had no prognostic significance.

However, the benefit of lymph node dissection after curative resection for ICC is controversial. Some studies have purported that the 5-year survival rate after surgery is 0% in the presence of lymph node metastases and that lymph node dissection was not beneficial [10,24,25]. In contrast, other studies found no significant difference between patients with and without lymph node metastases in terms of survival rates, and suggested that lymphadenectomy may be necessary to improve the prognosis of patients with ICC [6,11,26]. In the previous reports [10,24,25] suggesting a negative prognosis for node-positive patients, systematic regional lymphadenectomy was not completed in all patients and the presence or absence of PAN metastases was not described in detail. In the reports by Uenishi et al. [7] and Shirai et al. [27], all patients received regional

lymphadenectomy. A conclusion of these studies was that lymph node metastasis was an independent prognostic factor associated with a poor prognosis. However, in both series, systematic PAN dissection and pathological examination were performed in only approximately half of the total cases, so that the PAN status could not be clearly defined. PAN metastases is generally accepted as equivalent to distant metastasis and thus to represent a systemic disease [17-19]. Therefore, in the present study, we attempted to identify prognostic factors for survivorship in ICC patients without PAN and to evaluate the efficacy of lymphadenectomy in these patients by excluding patients with PAN metastases, as determined by pathological confirmation. Our results showed that lymph node status was not an independent prognostic factor, and indicate that curative liver resection with systematic regional lymphadenectomy improves the prognosis after surgery for node-positive patients without PAN metastases.

Our results are entirely the opposite of those of previous retrospective reports, and the ultimate difference from past studies was the elimination of PAN metastases. However, our study results do not represent conclusive evidence, because the number of patients was small and the study design was not a prospective. Hence, future large-scale studies will be needed to confirm our findings.

In the present study, the evaluation for PAN metastases was performed by intraoperative pathological examination, since preoperative diagnostic imaging techniques, including CT, MRI, and 18F-fluorodeoxyglucose positron-emission tomography, have difficulty in accurately detecting lymph node metastases preoperatively [28,29]. Although initially negative according to intraoperative frozen-section examinations, the PAN status was overturned by permanent-section

examinations in 2 patients in the current study. Regardless of these 2 false negative findings, the pathological examination remained the most useful diagnostic method available for excluding PAN metastasis. Other problems of intraoperative PAN dissection are time consumption and related morbidities. As the required time for PAN dissection depends on the numbers of dissected nodes, an accustomed surgeon could obtain results of pathological diagnosis 30-45 minutes after beginning of the PAN dissection. Although intractable ascites retention including chylous ascites is a common complication following paraaortic lymphadenectomy, it may be prevented by complete seal or ligation of the dissected stump of the retroperitoneum and surrounding tissues.

In our study, intraoperative transfusion was differentiated as an independent prognostic factor. Many authors have reported transfusion as a significant prognostic indicator after surgery for a number of malignancies, including gastric cancer [30,31], hepatocellular cancer [32,33], colorectal cancer [34], and pancreatic cancer [35]. However previous studies have not reported intraoperative transfusion an important prognostic factor for survival in patients with ICC. Evaluating the various possible associations between transfusion and prognosis after surgery is difficult; however, the immunosuppressive effect of transfusion may be more apparent after resection, as suggested by the results of animal studies [36]. Moreover, Clark et al. [37] commented that the requirements for intraoperative transfusion may reflect the technical difficulty involved in a larger or more advanced tumor, which would be associated with poor prognosis.

In conclusion, regional lymph node metastasis was not a significant prognostic factor for ICC in the absence of PAN metastases diagnosed by pathological confirmation. ICC with positive regional

lymph nodes and negative para-aortic lymph nodes should be a resectable disease.

## References

1. Primary liver cancer in Japan (1990) Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. *Ann Surg* 211:277-287
2. Chen MF (1999) Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. *J Gastroenterol Hepatol* 14:1144-1149
3. Ikai I, Itai Y, Okita K et al (2004) Report of the 15th follow-up survey of primary liver cancer. *Hepatol Res* 28:21-29
4. Khan SA, Thomas HC, Davidson BR et al (2005) Cholangiocarcinoma. *Lancet* 366:1303-1314
5. Okabayashi T, Yamamoto J, Kosuge T et al (2001) A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. *Cancer* 92:2374-2383
6. Nanashima A, Sumida Y, Abo T et al (2007) Patient outcome and prognostic factors in intrahepatic cholangiocarcinoma after hepatectomy. *Hepatogastroenterology* 54:2337-2342
7. Uenishi T, Kubo S, Yamazaki O et al (2008) Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. *J Hepatobiliary Pancreat Surg* 15:417-422
8. Tamandl D, Herberger B, Gruenberger B et al (2008) Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. *Ann Surg Oncol* 15:2787-2794

9. Lang H, Sotiropoulos GC, Sgourakis G et al (2009) Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. *J Am Coll Surg* 208:218-228
10. Zhang L, Cai JQ, Zhao JJ et al (2010) Impact of hepatitis B virus infection on outcome following resection for intrahepatic cholangiocarcinoma. *J Surg Oncol* 101:233-238
11. Miwa S, Miyagawa S, Kobayashi A et al (2006) Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. *J Gastroenterol* 41:893-900
12. Shen WF, Zhong W, Xu F et al (2009) Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. *World J Gastroenterol* 15:5976-5982
13. Guglielmi A, Ruzzenente A, Campagnaro T et al (2009) Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. *World J Surg* 33:1247-1254
14. Choi SB, Kim KS, Choi JY et al (2009) The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. *Ann Surg Oncol* 16:3048-3056
15. Shirabe K, Mano Y, Taketomi A et al (2010) Clinicopathological prognostic factors after hepatectomy for patients with mass-forming type intrahepatic cholangiocarcinoma: relevance of the lymphatic invasion index. *Ann Surg Oncol* 17:1816-1822
16. Uchiyama K, Yamamoto M, Yamaue H et al (2011) Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. *J Hepatobiliary Pancreat Sci* 18:443-452

17. Pedrazzoli S, DiCarlo V, Dionigi R et al (1998) Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. *Ann Surg* 228:508-517
18. Kondo S, Nimura Y, Hayakawa N et al (2000) Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. *Br J Surg* 87:418-422
19. Farnell MB, Aranha GV, Nimura Y et al (2008) The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence. *J Gastrointest Surg* 12:651-656
20. Shimada H, Endo I, Togo S et al (1997) The role of lymph node dissection in the treatment of gallbladder carcinoma. *Cancer* 79:892-899
21. Kitagawa Y, Nagino M, Kamiya J et al (2001) Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. *Ann Surg* 233:385-392
22. Sobin LH, Gospodarowicz MK, Wittekind C (2010) International Union Against Cancer (UICC) TNM classification of malignant tumours, 7th edition. New York: Wiley-Liss p.114-117.
23. Liver Cancer Study Group of Japan, Macroscopic gross type (2008) In: The general rules for the clinical and pathological study of primary liver cancer (5th edition), Kanehara, Tokyo, p. 17-18
24. Yamashita Y, Taketomi A, Morita K et al (2008) The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60

patients. *Anticancer Res* 28:2353-2359

25. Paik KY, Jung JC, Heo JS et al (2008) What prognostic factors are important for resected intrahepatic cholangiocarcinoma? *J Gastroenterol Hepatol* 23:766-770

26. Ohtsuka M, Ito H, Kimura F et al (2002) Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. *Br J Surg* 89:1525-1531

27. Shirai K, Ebata T, Oda K et al (2008) Perineural invasion is a prognostic factor in intrahepatic cholangiocarcinoma. *World J Surg* 32:2395-2402

28. Noji T, Kondo S, Hirano S et al (2005) CT evaluation of paraaortic lymph node metastasis in patients with biliary cancer. *J Gastroenterol* 40:739-743

29. Imai H, Doi R, Kanazawa H et al (2010) Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer. *Int J Clin Oncol* 15:294-300

30. Sugezawa A, Kaibara N, Sumi K et al (1989) Blood transfusion and the prognosis of patients with gastric cancer. *J Surg Oncol* 42:113-116

31. Ojima T, Iwahashi M, Nakamori M et al (2009) Association of allogeneic blood transfusions and long-term survival of patients with gastric cancer after curative gastrectomy. *J Gastrointest Surg* 13:1821-1830

32. Asahara T, Katayama K, Itamoto T et al (1999) Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. *World J Surg* 23:676-680

33. Makino Y, Yamanoi A, Kimoto T et al (2000) The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. *Am J Gastroenterol*

95:1294-1300

34. Chung M, Steinmetz OK, Gordon PH (1993) Perioperative blood transfusion and outcome after resection for colorectal carcinoma. *Br J Surg* 80:427-432
35. Yeh JJ, Gonen M, Tomlinson JS et al (2007) Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. *Br J Surg* 94:466-472
36. Salvadori S, Martinelli G, Zier K (2000) Resection of solid tumors reverses T cell defects and restores protective immunity. *J Immunol* 164:2214-2220
37. Clark E, Connor S, Taylor MA et al (2007) Perioperative transfusion for pancreaticoduodenectomy and its impact on prognosis in resected pancreatic ductal adenocarcinoma. *HPB (Oxford)* 9:472-477


## Figure caption


### Fig. 1

After *En bloc* resection of PANs. The resected connective tissue containing PANs were located between the levels of the celiac artery and inferior mesenteric Artery, and on the area between the aorta and the inferior vena cava. *IMA* inferior mesenteric artery; *IVC* inferior vena cava

### Fig. 2

Overall survival in case of lymph node positive and negative. Survival rate of 14 patients with lymph node metastasis is 20% at 5 years, while survival rate without lymph node metastasis is 31 % at 5 years.  $P = 0.0886$  (log rank test)





No. at risk

|       |    |    |    |   |
|-------|----|----|----|---|
| pN(-) | 33 | 29 | 10 | 5 |
| pN(+) | 14 | 10 | 4  | 2 |

Time after surgery (years)

**Table 1** Surgical procedures and additional resection in the 47 patients with ICC

| Procedure                                                              | Number | %   |
|------------------------------------------------------------------------|--------|-----|
| Segmentectomy                                                          | 0      | 0   |
| Bisegmentectomy (segments III,IV)                                      | 1      | 2   |
| Left lateral sectionectomy (segments II,III)                           | 1      | 2   |
| Right arterial sectionectomy (segments V,VIII)                         | 2      | 4   |
| Hemihepatectomy                                                        |        |     |
| Right hemihepatectomy (Segments V–VIII)                                | 3      | 6   |
| Right hemihepatectomy and caudate lobe resection (Segments I,V–VIII)   | 5      | 11  |
| Left hemihepatectomy (Segments II–IV)                                  | 1      | 2   |
| Left hemihepatectomy and caudate lobe resection (Segments I–IV)        | 27     | 58  |
| Trisectionectomy                                                       |        |     |
| Right trisectionectomy and caudate lobe resection (Segments I,IV–VIII) | 2      | 4   |
| Left trisectionectomy and caudate lobe resection (Segments I–V,VIII)   | 5      | 11  |
| Total                                                                  | 47     | 100 |

**Table 2** Univariate analysis of prognostic factors in 47 patients with ICC

| Factors                              | No. of patients | Actual survival numbers<br>(and overall survival rate) |            | Median survival time<br>(months) | Log rank test<br><i>P</i> -value |
|--------------------------------------|-----------------|--------------------------------------------------------|------------|----------------------------------|----------------------------------|
|                                      |                 | 3y-<br>(%)                                             | 5y-<br>(%) |                                  |                                  |
| Total                                | 47              | 14 (51)                                                | 7 (28)     | 37.5                             |                                  |
| Gender                               |                 |                                                        |            |                                  |                                  |
| Male                                 | 29              | 8 (44)                                                 | 4 (22)     | 31.9                             | 0.6243                           |
| Female                               | 18              | 6 (67)                                                 | 3 (40)     | 44.5                             |                                  |
| Age(years)                           |                 |                                                        |            |                                  |                                  |
| 65>                                  | 22              | 7 (44)                                                 | 2 (15)     | 31.9                             | 0.1340                           |
| 65≤                                  | 25              | 7 (59)                                                 | 5 (42)     | 59.1                             |                                  |
| Preoperative jaundice                |                 |                                                        |            |                                  |                                  |
| (+)                                  | 11              | 3 (55)                                                 | 3 (55)     | 66.4                             | 0.4075                           |
| (-)                                  | 36              | 11 (49)                                                | 4 (20)     | 33.9                             |                                  |
| Hepatitis virus                      |                 |                                                        |            |                                  |                                  |
| (+)                                  | 5               | 3 (60)                                                 | 2 (40)     | 46.4                             | 0.7599                           |
| (-)                                  | 42              | 11 (48)                                                | 5 (24)     | 33.9                             |                                  |
| ICG15R                               |                 |                                                        |            |                                  |                                  |
| 11>                                  | 25              | 8 (53)                                                 | 3 (23)     | 37.5                             | 0.4702                           |
| 11≤                                  | 22              | 6 (49)                                                 | 4 (33)     | 21.2                             |                                  |
| Preoperative CEA level               |                 |                                                        |            |                                  |                                  |
| 6.5>                                 | 36              | 11 (51)                                                | 6 (31)     | 37.5                             | 0.1431                           |
| 6.5≤                                 | 11              | 3 (55)                                                 | 1 (18)     | 44.5                             |                                  |
| Preoperative CA19-9 level            |                 |                                                        |            |                                  |                                  |
| 37>                                  | 16              | 5 (79)                                                 | 2 (43)     | 40.8                             | 0.2719                           |
| 37≤                                  | 31              | 9 (40)                                                 | 5 (22)     | 28.7                             |                                  |
| Concomitant portal vein resection    |                 |                                                        |            |                                  |                                  |
| (+)                                  | 8               | 1 (17)                                                 | 1 (17)     | 12.3                             | 0.0139                           |
| (-)                                  | 39              | 13 (58)                                                | 6 (29)     | 40.8                             |                                  |
| Concomitant hepatic artery resection |                 |                                                        |            |                                  |                                  |
| (+)                                  | 5               | 0 (0)                                                  | 0 (0)      | 9.9                              | 0.0011                           |
| (-)                                  | 42              | 14 (58)                                                | 7 (32)     | 40.8                             |                                  |
| Operation time                       |                 |                                                        |            |                                  |                                  |
| 630min>                              | 25              | 10 (63)                                                | 4 (28)     | 42.2                             | 0.1097                           |
| 630min≤                              | 22              | 4 (36)                                                 | 3 (27)     | 19.8                             |                                  |
| Blood loss                           |                 |                                                        |            |                                  |                                  |
| 1800cc>                              | 25              | 11 (66)                                                | 6 (36)     | 44.5                             | 0.0181                           |
| 1800cc≤                              | 22              | 3 (31)                                                 | 1 (20)     | 18.4                             |                                  |
| Intraoperative Transfusion           |                 |                                                        |            |                                  |                                  |
| (+)                                  | 20              | 2 (24)                                                 | 1 (24)     | 15.5                             | 0.0006                           |

|                             |    |         |        |      |         |
|-----------------------------|----|---------|--------|------|---------|
| (-)                         | 27 | 12 (70) | 6 (35) | 44.5 |         |
| Macroscopic gross type      |    |         |        |      |         |
| MF                          | 18 | 3 (32)  | 1 (11) | 21.2 | 0.2061* |
| MF+PI                       | 17 | 7 (63)  | 4 (36) | 42.2 |         |
| MF+IG                       | 3  | 1 (100) | 0 (0)  | 44.5 |         |
| IG                          | 5  | 2 (80)  | 1 (80) | —    |         |
| PI                          | 4  | 1 (25)  | 1 (25) | 28.7 |         |
| Tumor size                  |    |         |        |      |         |
| 50mm>                       | 25 | 7 (49)  | 4 (28) | 33.9 | 0.8652  |
| 50mm≤                       | 22 | 7 (52)  | 3 (27) | 37.5 |         |
| Macroscopic growth pattern  |    |         |        |      |         |
| eg                          | 17 | 6 (60)  | 2 (25) | 37.5 | 0.9613  |
| ig                          | 30 | 8 (46)  | 5 (29) | 33.9 |         |
| Tumor number                |    |         |        |      |         |
| St                          | 39 | 12 (50) | 7 (32) | 40.8 | 0.3735  |
| Mt                          | 8  | 2 (55)  | 0 (0)  | 37.5 |         |
| Lymph node metastases       |    |         |        |      |         |
| (+)                         | 14 | 4 (40)  | 2 (20) | 15.9 | 0.0886  |
| (-)                         | 33 | 10 (55) | 5 (31) | 34.1 |         |
| Liver capsular invasion     |    |         |        |      |         |
| (+)                         | 12 | 4 (48)  | 1 (12) | 33.9 | 0.3732  |
| (-)                         | 35 | 10 (53) | 6 (35) | 40.8 |         |
| Microscopic vessel invasion |    |         |        |      |         |
| (+)                         | 34 | 9 (42)  | 4 (19) | 31.9 | 0.1350  |
| (-)                         | 13 | 5 (74)  | 3 (56) | 81.1 |         |
| Perineural invasion         |    |         |        |      |         |
| (+)                         | 29 | 8 (41)  | 4 (20) | 31.9 | 0.1860  |
| (-)                         | 18 | 6 (69)  | 3 (42) | 46.4 |         |
| pStage(UICC)                |    |         |        |      |         |
| I,II,III                    | 21 | 5 (52)  | 2 (28) | 37.5 | 0.7415  |
| IVA, IVB                    | 26 | 9 (49)  | 5 (27) | 31.9 |         |
| Resection margin            |    |         |        |      |         |
| (+)                         | 6  | 0 (0)   | 0 (0)  | 15.5 | 0.0062  |
| (-)                         | 41 | 14 (58) | 7 (32) | 40.8 |         |

*ICG15R* indocyanin green retention rate after 15 minutes; *CEA* carcinoembryonic antigen; *CA19-9* carbohydrate antigen 19-9; *MF type* mass forming type; *PI type* periductal infiltrating type; *IG type* intraductal growth type

\*; Calculated between the MF type vs MF+PI type.

**Table 3** Multivariate analysis of prognostic factors after hepatic resection for ICC

| Prognostic factor                    | Risk ratio (95% CI)   | <i>P</i> -value |
|--------------------------------------|-----------------------|-----------------|
| Intraoperative transfusion           | 4.161 (1.517, 11.416) | 0.0056          |
| Blood loss (1800cc<)                 | 1.657 (0.595, 4.613)  | 0.3338          |
| Resection margin (positive)          | 1.122 (0.242, 5.200)  | 0.8828          |
| concomitant portal vein resection    | 2.212 (0.647, 7.559)  | 0.2053          |
| concomitant hepatic artery resection | 2.896 (0.536, 15.632) | 0.2164          |
| lymph node metastases (positive)     | 1.799 (0.719, 4.496)  | 0.2092          |

CI; confidence interval.